Daiwa Securities Group
RXRX icon

Daiwa Securities Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Daiwa Securities Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
68,900
+53,400
+345% +$178K ﹤0.01% 1063
2026
Q1 		$47.6K Buy
15,500
+13,788
+805% +$53.3K ﹤0.01% 1110
2025
Q4 		$7K Sell
1,712
-9,995
-85% -$49.5K ﹤0.01% 1211
2025
Q3 		$57K Sell
11,707
-999
-8% -$5.25K ﹤0.01% 1084
2025
Q2 		$64K Buy
12,706
+2,883
+29% +$14.2K ﹤0.01% 1039
2025
Q1 		$52K Sell
9,823
-312
-3% -$2.27K ﹤0.01% 1018
2024
Q4 		$69K Buy
10,135
+2,235
+28% +$15K ﹤0.01% 1024
2024
Q3 		$52K Buy
7,900
+32
+0.4% +$229 ﹤0.01% 1065
2024
Q2 		$59K Sell
7,868
-3,214
-29% -$28K ﹤0.01% 1086
2024
Q1 		$110K Sell
11,082
-677
-6% -$7.54K ﹤0.01% 1042
2023
Q4 		$116K Buy
11,759
+11,028
+1,509% +$78.6K ﹤0.01% 996
2023
Q3 		$6K Hold
731
– – ﹤0.01% 1146
2023
Q2 		$5K Sell
731
-7,680
-91% -$53.7K ﹤0.01% 1185
2023
Q1 		$56K Buy
8,411
+1,508
+22% +$12K ﹤0.01% 1039
2022
Q4 		$53K Buy
6,903
+6,292
+1,030% +$61.7K ﹤0.01% 1031
2022
Q3 		$7K Sell
611
-11,584
-95% -$117K ﹤0.01% 1147
2022
Q2 		$99K Buy
12,195
+4,954
+68% +$33.1K ﹤0.01% 1025
2022
Q1 		$52K Buy
7,241
+2,127
+42% +$22.6K ﹤0.01% 1085
2021
Q4 		$88K Buy
+5,114
New +$96.2K ﹤0.01% 1029

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Daiwa Securities Group's RXRX Position: Q2 2026 in Review

Daiwa Securities Group increased its Recursion Pharmaceuticals (RXRX) stake by 345% in Q2 2026, buying an estimated $178K and bringing the position to 68,900 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

Daiwa Securities Group first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Daiwa Securities Group held 68,900 shares of Recursion Pharmaceuticals worth $253K as of Q2 2026.
  • Daiwa Securities Group bought 53,400 Recursion Pharmaceuticals shares in Q2 2026, an estimated $178K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #1063 holding.
  • Daiwa Securities Group first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.